128 related articles for article (PubMed ID: 11347950)
1. Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.
Farina C; Gagliardi S; Nadler G; Morvan M; Parini C; Belfiore P; Visentin L; Gowen M
Farmaco; 2001; 56(1-2):113-6. PubMed ID: 11347950
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
Farina C; Gagliardi S
Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
[TBL] [Abstract][Full Text] [Related]
3. 5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.
Gagliardi S; Nadler G; Consolandi E; Parini C; Morvan M; Legave MN; Belfiore P; Zocchetti A; Clarke GD; James I; Nambi P; Gowen M; Farina C
J Med Chem; 1998 May; 41(10):1568-73. PubMed ID: 9572882
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
Niikura K; Takano M; Sawada M
Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
[TBL] [Abstract][Full Text] [Related]
5. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.
Visentin L; Dodds RA; Valente M; Misiano P; Bradbeer JN; Oneta S; Liang X; Gowen M; Farina C
J Clin Invest; 2000 Jul; 106(2):309-18. PubMed ID: 10903347
[TBL] [Abstract][Full Text] [Related]
6. (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.
Nadler G; Morvan M; Delimoge I; Belfiore P; Zocchetti A; James I; Zembryki D; Lee-Rycakzewski E; Parini C; Consolandi E; Gagliardi S; Farina C
Bioorg Med Chem Lett; 1998 Dec; 8(24):3621-6. PubMed ID: 9934482
[TBL] [Abstract][Full Text] [Related]
7. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
8. [3H]Bafilomycin as a probe for the transmembrane proton channel of the osteoclast vacuolar H(+)-ATPase.
Mattsson JP; Keeling DJ
Biochim Biophys Acta; 1996 Apr; 1280(1):98-106. PubMed ID: 8634321
[TBL] [Abstract][Full Text] [Related]
9. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of bafilomycin A1 derivatives as inhibitors of vacuolar H+-ATPase.
Gagliardi S; Gatti PA; Belfiore P; Zocchetti A; Clarke GD; Farina C
J Med Chem; 1998 May; 41(11):1883-93. PubMed ID: 9599238
[TBL] [Abstract][Full Text] [Related]
11. Chemistry and structure activity relationships of bafilomycin A1, a potent and selective inhibitor of the vacuolar H+-ATPase.
Gagliardi S; Rees M; Farina C
Curr Med Chem; 1999 Dec; 6(12):1197-212. PubMed ID: 10519916
[TBL] [Abstract][Full Text] [Related]
12. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
[TBL] [Abstract][Full Text] [Related]
13. A pharmacological assessment of the mammalian osteoclast vacuolar H(+)-ATPase.
Hall TJ; Schaueblin M
Bone Miner; 1994 Nov; 27(2):159-66. PubMed ID: 7711523
[TBL] [Abstract][Full Text] [Related]
14. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
15. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
16. The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis.
Yuan FL; Li X; Lu WG; Li CW; Li JP; Wang Y
Mol Biol Rep; 2010 Oct; 37(7):3561-6. PubMed ID: 20182803
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibitors of the osteoclast vacuolar proton ATPase as novel bone antiresorptive agents.
Farina C; Gagliardi S
Drug Discov Today; 1999 Apr; 4(4):163-172. PubMed ID: 10322275
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibitors of vacuolar H(+)-ATPase trigger apoptotic cell death of osteoclasts.
Okahashi N; Nakamura I; Jimi E; Koide M; Suda T; Nishihara T
J Bone Miner Res; 1997 Jul; 12(7):1116-23. PubMed ID: 9200012
[TBL] [Abstract][Full Text] [Related]
19. [V-ATPase inhibitor baflomycine A1 inhibits bone resorption by osteoclast-like cells].
Zhao N; Yu S
Zhonghua Bing Li Xue Za Zhi; 1999 Dec; 28(6):436-9. PubMed ID: 11869558
[TBL] [Abstract][Full Text] [Related]
20. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
